Well done to all six teams from Domainex who took on the 3 Peaks challenge to raise money for Tŷ Hafan! This amazing charity helps life-limited children in Wales to make the most of the time they have left together with their families.
There is still time to donate: https://www.justgiving.com/team/Domainex3peaks?invite=true
Bicycle Therapetuics and MRC Laboratory of Molecular Biology have shared a recent publication in Nature Communications describing the effectiveness of Bicycles as antivirals against SARS-CoV-2.
Read the full publication here: https://www.nature.com/articles/s41467-023-39158-1.epdf?sharing_token=M…
Discover state-of-the-art Category II wet lab space, co-loacted with world experts in vaccines and stemcells at the Royal Veterinary College's (RVC) Centre for Vaccinology and Regenerative Medicine (CVRM) in the beautiful Hertfordshire countryside.
Read more: https://www.lbic.com/lbic-cvrm
17 June 2023
Professor Ian Charles, Director of the Quadram Institute in Norwich, UK, has been recognised for a lifetime of pioneering research with an OBE (Order of the British Empire) in the King’s birthday honours.
Prof Charles has been awarded his OBE for Services to science and clinical research during a distinguished career in the biomedical sector. An internationally recognised academic scientist, entrepreneur and business leader, Ian has more than 30 years’ experience in academic and commercial research with a focus on infectious diseases, the microbiome, and…
ValiRx PLC, a life science company focused on early-stage cancer therapeutics and women’s health, has announced the acquisition of the scientific assets of Imagen Therapeutics Limited from its appointed liquidators for £170,000.
UK pharmaceutical services company Imagen offered personalised cancer treatment through the collection and use of well-characterised, patient-derived cells.
The company collected samples from patients over a number of years across a wide variety of cancers and was able to build a unique ‘biobank’ of human derived cells and provide services to the global pharmaceutical…
• Collaboration to accelerate and de-risk clinical development of Nanopharmaceutics CNS portfolio.
• Agreement to utilize PrecisionLife’s combinatorial analytics platform to identify genetic biomarkers that will optimize patient selection across multiple CNS clinical trials.
Oxford, UK, and Alachua, US, 15 June 2023 – PrecisionLife, a leading techbio company driving precision medicine into complex chronic diseases, and Nanopharmaceutics, Inc., a clinical-stage pharmaceutical development company, announced today a strategic collaboration aiming to accelerate and de-risk the development of…
AMSBIO is a leading provider of ready-to-use Adeno-Associated Virus (AAV) that can be engineered to efficiently deliver specific DNA sequences into target cells with a low immunogenicity.
Drawing upon years of experience – AMSBIO have developed a robust AAV Production Service providing researchers with access to the highest quality recombinant AAV vectors that can efficiently transfect multiple cell types, including dividing and non-dividing cells. These AAV vectors induce persistent gene expression in vivo without integrating into the host genome or causing any disease. These features make…
Optimer binders have been successfully developed to a novel Alzheimer’s disease biomarker
Aptamer Group CTO, Dr David Bunka, will present at Neuro-Bio’s Science Day on Optimer technology and the development of binders to support the diagnostic
York, UK (June 14, 2023) – Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, and Neuro-Bio, an Oxford-based biotechnology company with a therapeutic focus on neurodegenerative disease, announce success in the development of Optimer binders to enable a…